Modeling the epidemiological impact of different adult pneumococcal vaccination strategies in the United Kingdom
Oidtman, R. J.; Meleleo, G. J.; Sharomi, O.; Matthews, I.; Ntais, D.; Nachbar, R.; Malik, T.; Bakker, K. M.
Show abstract
BackgroundPneumococcal conjugate vaccines (PCVs) were first introduced in the pediatric United Kingdom (UK) immunisation programme in 2006 which led to significant declines in invasive pneumococcal disease (IPD) caused by targeted serotypes. Although pediatric PCVs provide some indirect protection to adults, a significant IPD burden remains in older adults. Here, we compared three adult (65+ years-old) and risk group (2-64-year-old) vaccination scenarios, namely a continuation of the status quo with PPSV23 vaccination, using the recently licensed-in-adults PCV20, or using the new adult-focused 21-valent PCV, V116. MethodsA population-level compartmental dynamic transmission model (DTM) was adapted to the UK setting. The model described Streptococcus pneumoniae carriage transmission dynamics and disease progression in the presence of age- and serotype-specific pneumococcal vaccines. We calibrated the DTM to age- and serotype-specific IPD data in the UK and used the model to make projections under the different adult vaccination scenarios, while keeping PCV13 immunization in children. ResultsThe calibrated model yielded reasonable parameter values and model fits that closely matched observed IPD dynamics. Among 65+ year-olds, routine use of V116 averted more cases of IPD than PCV20 or PPSV23 vaccination. There was a notable decrease in IPD incidence in the serotypes unique to V116. In the serotypes included in PCV20 but not V116, the model did not predict a resurgence of IPD. ConclusionsProjections revealed that in adults, V116 led to greater reductions in IPD in the 65+ year-old population compared with PCV20 or PPSV23. HIGHLIGHTSO_LIA dynamic transmission model was able to replicate historical pneumococcal dynamics. C_LIO_LIAn adult specific PCV (V116) in the UK would avert more pneumococcal disease than other candidate adult vaccines. C_LIO_LIThe dynamic model predicted no resurgence of serotypes not included in V116. C_LI
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada 95%
- Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19 95%
- Cost-effectiveness of routine COVID-19 adult vaccination programmes in England 95%
Similar papers in this journal
Similar papers in this journal
- Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis 94%
- Projecting vaccine demand and impact for emerging zoonotic pathogens 94%
- Potential health and economic impact of paediatric vaccination using next generation influenza vaccines in Kenya: a modelling study 94%
Similar papers in this journal
- Reducing RSV hospitalisation in a lower-income country by vaccinating mothers-to-be and their households 92%
- Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries 92%
- Estimating the transmissibility of SARS-CoV-2 during periods of high, low and zero case incidence 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.